James K Olson

US Patent:

6482223, Nov 19, 2002

Filed:

Jun 1, 2000

Appl. No.:

09/585488

Inventors:

Karol L. Nowakowski - Circle Pines MN
James E. Olson - Eagan MN
Edward T. Joseph - Inver Grove Heights MN
Daniel G. Ericson - Rochester MN

Assignee:

Closys Corporation - Edina MN

International Classification:

A61B 1704

US Classification:

606213, 424530, 210782, 210651, 422 44

Abstract:

Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anti-coagulating agents and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed. The present invention provides improved methods of creating hemostasis or control of bleeding at the site of wounds, particularly wounds created in arteries during procedures employing percutaneous access. The invention preferably includes the steps of acquiring an aliquot of a patients blood, i. e. , autologous blood, removing a negatively charged anti-coagulating agent, preferably heparin, from the blood, and preferably initiating the bloods natural clotting cascades and transporting the thus treated blood to the site of the wound where the clotting cascade will be completed producing a clot at the wound site that will create a condition of hemostasis.

US Patent:

6569517, May 27, 2003

Filed:

Nov 17, 2000

Appl. No.:

09/714932

Inventors:

Daniel J. McGurran - Woodbury MN
Laurence R. Gilbert - Marine on St. Croix MN
Bryan L. Klaenhammer - River Falls WI
James A. Olson - Maplewood MN

Assignee:

3M Innovative Properties Company - St. Paul MN

International Classification:

B32B 516

US Classification:

428323, 359582, 359585, 359589, 428328, 428336, 428337, 428458

Abstract:

A color-tailorable, surface-metalized, pigmented optical body comprising a single or multiple layer polymeric core comprising at least one layer of a thermoplastic polymer material having dispersed therein a particulate pigment, and a metallic layer located on at least one outer surface of the polymeric core. The optical bodies are generally constructed such that the at least one of the L*, a*, and b* color scales of the polymeric core differs from the L*, a*, and b* color scales of the metallic layer.

US Patent:

6811867, Nov 2, 2004

Filed:

Aug 8, 2000

Appl. No.:

09/633911

Inventors:

Daniel J. McGurran - Woodbury MN
Robert L. Brott - Woodbury MN
James A. Olson - Maplewood MN

Assignee:

3M Innovative Properties Company - St. Paul MN

International Classification:

B32B 2718

US Classification:

428323, 428328, 428329, 428330, 428331, 428480, 359885

Abstract:

Color-stable, pigmented optical bodies comprising a single or multiple layer core having at least one layer of a thermoplastic polymer material. The thermoplastic polymer material has dispersed within it a particulate pigment. The optical bodies generally possess high clarity and low haze and exhibit a transmission of light within a wavelength band of interest within the visible spectrum of from about 10 to about 90 percent.

US Patent:

7368161, May 6, 2008

Filed:

Aug 23, 2004

Appl. No.:

10/923901

Inventors:

Daniel J. McGurran - Woodbury MN, US
Robert L. Brott - Woodbury MN, US
James A. Olson - Maplewood MN, US

Assignee:

3M Innovative Properties Company - St. Paul MN

International Classification:

B32B 27/18
B32B 27/20
B32B 27/36

US Classification:

428215, 428212, 428213, 428323, 428332, 428334, 428337, 428339, 428480, 428910, 359885

Abstract:

Color-stable, pigmented optical bodies comprising a single or multiple layer core having at least one layer of a thermoplastic polymer material. The thermoplastic polymer material has dispersed within it a particulate pigment. The optical bodies generally possess high clarity and low haze and exhibit a transmission of light within a wavelength band of interest within the visible spectrum of from about 10 to about 90 percent.

US Patent:

8282620, Oct 9, 2012

Filed:

Feb 5, 2009

Appl. No.:

12/366165

Inventors:

James M. Olson - Plymouth MN, US
Michael Hegland - Mounds View MN, US
Dale F. Seeley - Spring Park MN, US

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

A61B 19/00
B65B 1/04
B65B 3/04

US Classification:

604408, 604403, 141 10

Abstract:

A container for housing a fluid therapeutic composition includes a rigid housing, a collapsible bag and a seal. The housing has an opening and an interior surface. The interior surface forms a cavity having a volume. The bag is disposed in the housing and is expandable to contact the interior surface of the housing and occupy the entire volume of the cavity when filled with the fluid therapeutic composition. The bag has an opening that is fixed in proximity to the opening of the housing. The seal is configured to prevent air from entering the bag via the bag opening and to prevent air from entering the cavity of the housing via the housing opening.

US Patent:

8343084, Jan 1, 2013

Filed:

Oct 29, 2010

Appl. No.:

12/915822

Inventors:

Karol L. Nowakowski - Circle Pines MN, US
James E. Olson - Eagan MN, US
Edward T. Joseph - Inver Grove Heights MN, US
Daniel G. Ericson - Rochester MN, US

Assignee:

Closys Corporation - St. Paul MN

International Classification:

A61M 37/00
A61M 31/00
A61B 19/00
A61K 31/74
A61K 47/48

US Classification:

604 401, 604 501, 604 607, 604 609, 604 612, 604 615, 604 616, 604522, 604403, 424 7808, 424 7809, 424 781, 424 7817, 424 7826

Abstract:

A wound closure apparatus and associated methods are provided which utilize blood fluid by activating the clotting cascade of blood fluid within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. An apparatus for providing ways of inhibiting anticoagulating agents and slowing fibrin clot degradation are also disclosed. Kits are also disclosed. The invention provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid. In further embodiments, the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.

US Patent:

20030017326, Jan 23, 2003

Filed:

Jun 1, 2001

Appl. No.:

09/872532

Inventors:

Daniel McGurran - Woodbury MN, US
James Olson - Maplewood MN, US
Mark Schaeffer - Hudson WI, US

Assignee:

3M Innovative Properties Company

International Classification:

B32B005/16
B32B027/36

US Classification:

428/323000, 428/328000, 428/329000, 428/331000, 428/480000

Abstract:

Color-stable, pigmented optical bodies comprising a single or multiple layer core having at least one layer of a thermoplastic polymer material. The thermoplastic polymer material has dispersed within it a particulate pigment. The optical bodies generally possess high clarity and low haze and exhibit a transmission of light within a wavelength band of interest within the visible spectrum of from about 10 to about 90 percent. The optical bodies also comprise one or more dyes in an amount sufficient to adjust transmitted color, by no more than about 15 units of the color coordinate a* and no more than about 15 units of the color coordinate b*, to a target color such as neutral gray.

US Patent:

20030069601, Apr 10, 2003

Filed:

Nov 12, 2002

Appl. No.:

10/291965

Inventors:

Karol Nowakowski - Circle Pines MN, US
James Olson - Eagan MN, US
Edward Joseph - Inver Grove Heights MN, US
Daniel Ericson - Rochester MN, US

Assignee:

Closys Corporation

International Classification:

A61B017/08

US Classification:

606/214000

Abstract:

Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anti-coagulating agents and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed. The present invention provides improved methods of creating hemostasis or control of bleeding at the site of wounds, particularly wounds created in arteries during procedures employing percutaneous access. The invention preferably includes the steps of acquiring an aliquot of a patient's blood, i.e., autologous blood, removing a negatively charged anti-coagulating agent, preferably heparin, from the blood, and preferably initiating the blood's natural clotting cascades and transporting the thus treated blood to the site of the wound where the clotting cascade will be completed producing a clot at the wound site that will create a condition of hemostasis. The invention further provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid. In further embodiments the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.